P78.05 Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome

Authors :: Bryan J. Schneider
David P. Carbone
B Pannecouk
Lili Zhao
Gabrielle Lopez
Dawn Owen
Nithya Ramnath
Peter G. Shields
Gregory P. Kalemkerian
Kai He
Mingjia Li
C Wood
Sandip H. Patel
Angel Qin
Shirish M. Gadgeel
Erin M. Bertino
Madison Grogan
Greg Otterson
N. Surya
Carolyn J Presley
Source :: Journal of Thoracic Oncology. 16:S639-S640
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
business.industry
Incidence (epidemiology)
Internal medicine
First line
medicine
Pembrolizumab
business
Outcome (game theory)

Full Text Access

Tools